[go: up one dir, main page]

WO2019074464A3 - The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 - Google Patents

The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 Download PDF

Info

Publication number
WO2019074464A3
WO2019074464A3 PCT/TR2018/050568 TR2018050568W WO2019074464A3 WO 2019074464 A3 WO2019074464 A3 WO 2019074464A3 TR 2018050568 W TR2018050568 W TR 2018050568W WO 2019074464 A3 WO2019074464 A3 WO 2019074464A3
Authority
WO
WIPO (PCT)
Prior art keywords
dapoxetine
pharmaceutical combination
phosphodiesterase type
polymorph
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050568
Other languages
French (fr)
Other versions
WO2019074464A2 (en
Inventor
Ali TÜRKYILMAZ
Arzu Palantöken
Dicle Güner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montero Gida Sanayi Ve Ticaret AS
Original Assignee
Montero Gida Sanayi Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montero Gida Sanayi Ve Ticaret AS filed Critical Montero Gida Sanayi Ve Ticaret AS
Priority to EP18865578.1A priority Critical patent/EP3694519A4/en
Publication of WO2019074464A2 publication Critical patent/WO2019074464A2/en
Publication of WO2019074464A3 publication Critical patent/WO2019074464A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical combination comprising dapoxetine or a pharmaceutically acceptable salt, solvate or polymorph thereof and a PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or polymorph thereof having a release profile comprises both immediate release and modified release.
PCT/TR2018/050568 2017-10-09 2018-10-08 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 Ceased WO2019074464A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18865578.1A EP3694519A4 (en) 2017-10-09 2018-10-08 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/15231A TR201715231A2 (en) 2017-10-09 2017-10-09 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
TR2017/15231 2017-10-09

Publications (2)

Publication Number Publication Date
WO2019074464A2 WO2019074464A2 (en) 2019-04-18
WO2019074464A3 true WO2019074464A3 (en) 2019-05-31

Family

ID=66100099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050568 Ceased WO2019074464A2 (en) 2017-10-09 2018-10-08 The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Country Status (3)

Country Link
EP (1) EP3694519A4 (en)
TR (1) TR201715231A2 (en)
WO (1) WO2019074464A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112263581A (en) * 2020-11-29 2021-01-26 长沙晶易医药科技有限公司 Double-layer tablet compound preparation for treating PE and ED and preparation method thereof
CN116687888A (en) * 2023-06-02 2023-09-05 苏州易合医药有限公司 Vardenafil and dapoxetine compound dry powder inhalation preparation and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038217A1 (en) * 2004-10-05 2006-04-13 Strides Acrolab Limited An improved drug delivery system of citalopram hydrobromide and process for producing the same
AU2006233567A1 (en) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Therapeutic combination in case of benign prostate hyperplasia
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine
CN103550775A (en) * 2013-10-18 2014-02-05 广州共禾医药科技有限公司 Anti-insomnia composition, application of composition, multi-phase pulse immediate-release preparation prepared by use of composition and preparation method of preparation
EP2698147A1 (en) * 2012-08-17 2014-02-19 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Film Formulations Comprising Dapoxetine and Tadalafil
CN106727439A (en) * 2016-12-21 2017-05-31 河南中帅医药科技股份有限公司 A kind of memantine is sustained donepezil quick-release compound capsule
TR201620151A2 (en) * 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130095180A1 (en) * 2010-07-06 2013-04-18 Navipharm. Co., Ltd. Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
US20150216798A1 (en) * 2012-08-17 2015-08-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038217A1 (en) * 2004-10-05 2006-04-13 Strides Acrolab Limited An improved drug delivery system of citalopram hydrobromide and process for producing the same
AU2006233567A1 (en) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Therapeutic combination in case of benign prostate hyperplasia
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine
EP2698147A1 (en) * 2012-08-17 2014-02-19 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Film Formulations Comprising Dapoxetine and Tadalafil
CN103550775A (en) * 2013-10-18 2014-02-05 广州共禾医药科技有限公司 Anti-insomnia composition, application of composition, multi-phase pulse immediate-release preparation prepared by use of composition and preparation method of preparation
CN106727439A (en) * 2016-12-21 2017-05-31 河南中帅医药科技股份有限公司 A kind of memantine is sustained donepezil quick-release compound capsule
TR201620151A2 (en) * 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN

Also Published As

Publication number Publication date
EP3694519A4 (en) 2021-10-20
WO2019074464A2 (en) 2019-04-18
EP3694519A2 (en) 2020-08-19
TR201715231A2 (en) 2019-04-22

Similar Documents

Publication Publication Date Title
EP3723743A4 (en) The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
FIC20253012I1 (en) A combination comprising (a) vantacaftor or a pharmaceutically acceptable salt thereof, preferably the calcium salt, (b) tezacaftor or a pharmaceutically acceptable salt thereof, and (c) deutivacaftor or a pharmaceutically acceptable salt thereof
SA520411990B1 (en) Compounds useful for inhibiting cyclin-dependent kinase 7
EP4656249A3 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
CA2902403C (en) Pde3/pde4 inhibitor/muscarinic receptor antagonist combination
EP3741374A4 (en) Mtor inhibitor, pharmaceutical composition and use thereof
HUE062277T2 (en) RIP1 inhibitor compounds and their preparation and use
WO2016205738A3 (en) Delivery systems for controlled drug release
EP3327014A4 (en) Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
EP3964512A4 (en) CASEIN KINASE 1epsilon INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
WO2019194773A3 (en) The combination comprising linagliptin and metformin
EP3849992A4 (en) Cd73 inhibitors and pharmaceutical uses thereof
IL275935B2 (en) Thiophene-triazol-piperidine-2,6-dione compound, a medicament comprising the compound, a pharmaceutical composition and the compound for use
WO2019074464A3 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
WO2017188720A3 (en) Quinazoline derivative or its salt and pharmaceutical composition comprising the same
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
WO2021111311A3 (en) Novel adamantane derivatives as inhibitors of focal adhesion kinase
WO2018096525A3 (en) Heteroaryl compounds and uses thereof
EP3851438A4 (en) Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
PH12020500228A1 (en) Pharmacutical composition comprising remogliflozin and antidiabetic agent
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
EP4308561A4 (en) Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
WO2017191619A3 (en) A process for the preparation of a salt of sacubitril and valsartan
WO2016108507A3 (en) Composite tablet for oral administration comprising melatonin and sertraline
EP3786161A4 (en) Cdk4/6 inhibitor and pharmaceutically acceptable salt and polymorph thereof and use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018865578

Country of ref document: EP

Effective date: 20200511